Compare BIRD & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIRD | GRDX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 28.6M |
| IPO Year | 2021 | 2016 |
| Metric | BIRD | GRDX |
|---|---|---|
| Price | $1.94 | $4.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 459.6K | 107.9K |
| Earning Date | 11-13-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.22 | ★ 21.95 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $152,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $487.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.05 | $1.87 |
| 52 Week High | $24.31 | $6.93 |
| Indicator | BIRD | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 31.60 | 54.68 |
| Support Level | N/A | $2.37 |
| Resistance Level | $2.54 | $5.04 |
| Average True Range (ATR) | 0.14 | 0.58 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 2.20 | 44.09 |
Smartbird Inc delivers dedicated AI infrastructure as a service, giving organizations the performance, control, and security of a private AI cluster without requiring them to finance, operate, or maintain the underlying infrastructure. Smartbird manages the entire lifecycle, from procurement and deployment to operations and hardware refreshes, so customers can focus on AI workloads, not AI infrastructure.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.